Selecting a Treatment Regimen
Table 6. Influenza Antiviral Medication Dosing
Recommendations
(Current and frequently updated information on antiviral
resistance and recommendations on antiviral use may be
found at http://www.cdc.gov/flu)
Neuraminidase
Inhibitors
(Brand)
Oseltamivir
(Tamiflu®)
(75-mg capsule;
60 mg/5-mL
suspension)a
Zanamivir
(Relenza®)
(Diskhaler:
5 mg per
inhalation)
a
Treatment
(Duration: 5 days)
Age
Adults and
adolescents
Children:
1–12 y
2–51 wk
Adults and
adolescents
Children
75 mg capsule twice a day
≤15 kg
60 mg/d
divided
into
2 doses
15–23 kg
>23–40 kg
90 mg/d
120 mg/d
divided
divided
into
into
2 doses
2 doses
3 mg/kg twice a day
>40 kg
150 mg/d
divided
into
2 doses
2 inhalations (10 mg) twice a day
≥7 y
2 inhalations (10 mg) twice a day
See package insert for dosages in patients with renal impairment.
Outbreak Management in Institutional Settings
ÎÎDuring influenza season, when 2 or more institutional residents
manifest signs and symptoms of influenza-like illness within 72 hours,
testing for influenza should occur (A-II).
ÎÎWhen influenza viruses are circulating in the community, even 1 positive
laboratory test result in conjunction with other compatible illnesses on
the unit indicates an outbreak of influenza is occurring (A-II).
ÎÎPersons developing compatible symptoms >72 hours after
implementation of antiviral chemoprophylaxis or among persons
residing on previously unaffected units should be tested for influenza
and other respiratory pathogens. If influenza testing is positive,
consider the possibility of a drug-resistant virus, spread of influenza
to previously unaffected areas of the facility where antiviral use has
not been implemented, or multiple introductions of influenza from the
community to facility residents (B-III).
10
